ClinicalTrials.gg
CompletedNCT01109524Updated Dec 24, 2015Results posted

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of Cetuximab and Cisplatin in Lung Neoplasms, Carcinoma and Cancer of the Lung, sponsored by Eli Lilly and Company. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-24.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 51
72 · median 63
Started
2010
with 3 others
Phase 2
31 of 52
1 open now
Registered
44th of 52
by date
Lead sponsor
13 of 52
Eli Lilly and Company

Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2010, is one of 31 in phase 2, and was the 44th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.

03

Conditions studied

  • Lung Neoplasms
  • Carcinoma
  • Cancer of the Lung
  • Non-Small-Cell Lung Carcinoma

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 72 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-Small Cell Lung Cancer (NSCLC), Stage IV (per the American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition) or recurrent disease following surgery and/or radiation therapy
  • Evaluable or
  • (ECOG) performance status of 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled Central Nervous System (CNS) .
  • Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy
  • Concurrent
  • Prior chemotherapy for NSCLC
  • Pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2
  • Superior vena cava syndrome contra-indicating hydration
  • White Blood Cells (WBC) \< 3,000/mm³
  • Absolute neutrophile count (ANC) \< 1,500/mm³
  • \< 100,000/mm³
  • (Hgb) \< 9.0 g/dL
  • Total > 1.5 x (ULN).
  • (AST) or Alanine-aminotransferase (ALT) > 5.0 x ULN.
  • Serum creatinine >1.25 x ULN and calculated \<60mL/min
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cetuximab + Cisplatin + Vinorelbine

    Drug: Cetuximab · Drug: Cisplatin · Drug: Vinorelbine

Interventions

  • Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision

    Also known as: Erbitux, BMS-564717

  • Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles

    Also known as: Platinol

  • Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles

    Also known as: Navelbine

07

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

    Time frame: Day 1 up to 30 days after last dose

  2. Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population

    Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (includes all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several preferred/other level MedDRA terms (MedDRA version 14.0). Except for Grade (GR)3 and 4 infusion reactions, AE severity were graded per the NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Severity of Gr 3 - 4 infusion reactions were: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=a life-threatening event characterized by the same symptomatology as a Gr 3, complicated by symptomatic hypotension or oxygen saturation 70% or less. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

    Time frame: Day 1 to 30 days after last dose

  3. Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population

    ULN=Upper limit of normal among all laboratory ranges. ALT=alanine transaminase; AST=aspartate aminotransferase; ALP=alkaline phosphatase. CTC grade criteria: ALT Grade 1:\>ULN 2.5\*ULN; Grade 2: \>2.5 - 5.0\*ULN; Grade 3: \>5.0 - 20.0\*ULN; Grade 4: \>20.0\*ULN. AST Grade 1: \>ULN - 2.5\*ULN; Grade 2: \>2.5 - 5.0\*ULN; Grade 3: \>5.0 - 20.0\*ULN; Grade 4: \>20.0\*ULN. Total bilirubin Grade 1: \>ULN - 1.5\*ULN; Grade 2: \>1.5 - 3.0\*ULN; Grade 3: \>3.0 - 10.0\*ULN; Grade 4: \>10.0\*ULN. Albumin (low) Grade 1:\<LLN - 3 grams per deciliter (g/dL)to \<LLN - 3 g/dL; Grade 2: \<3 - 2 g/dL to \< 3.0 - 2.0 g/dL; Grade 3: \< 2 g/dL to \<2 g/L. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

    Time frame: Day 1 up to 30 days after last dose

  4. Number of Participants With Hematology Laboratory Abnormalities - Treated Population

    Hematology laboratories included hemoglobin, platelets, white blood cell (WBC) count, and absolute neutrophil count (ANC) and values were per CTC grading, 0, 1, 2, 3, 4. On-study laboratory tests were those performed after the start of study drug (from Day 2 of cycle 1) and up to 30 days after the last dose of study drug. WBC normal range: 4.1-12.3 x 10\^3 /microliter (µL); platelets normal range: 140-450 x 10\^9 /Liter (L); hemoglobin normal range 14-18 grams per deciliter (g/dL); ANC normal range: 2.03-8.36 x 10\^9/μL.

    Time frame: Day 2 up to 30 days after last dose

  5. Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population

    ULN=Upper limit of normal among all laboratory ranges; LLN=Lower limit of normal. CTC grade criteria: Sodium high (H) Grade (Gr) 1:\>ULN - 150 millimoles per liter (mmol/L); Gr 2: \>150 - 155 mmol/L; Gr 3: \>155 - 160mmol/L; Gr 4: \>160 mmol/L. Sodium low(L) Gr 1:\<LLN - 130mmol/L; Gr 3: \<130 - 120 mmol/L; Gr 4: \<120 mmol/L. Potassium (H) Gr 1: \>ULN - 5.5 mmol/L; Gr 2: \>5.5 - 6.0 mmol/L; Gr 3: \> 6.0 - 7.0 mmol/L; Gr 4: \>7.0 mmol/L. Potassium (L) Gr 1: \<LLN - 3.0 mmol/L; Gr 2: \<LLN - 3.0 mmol/L; Gr 3: \< 3.0 - 2.5 mmol/L; Gr 4: \<2.5 mmol/L. Serum creatinine (H) Gr 1: \>1 - 1.5\*baseline (BL)to \>ULN - 1.5\*ULN; Gr 2: \>1.5 - 3.0\*BL to \> 1.5 - 3.0\*ULN; Gr 3: \>3.0\*BL to \> 3.0 - 6.0\*ULN; Gr 4: \>6.0\*ULN. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.

    Time frame: Day 1 up to 30 days after last dose

  6. Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population

    Drug-related AEs and drug-related SAEs (by investigator assessment) were those with a relationship to study drug(s) reported to Sponsor as related and those of unknown relationship. AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE was defined as a medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.

    Time frame: Day 1 up to 30 days after last dose

  7. Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population

    Drug-related AEs (investigator assessment): those with relationship to study drug(s)reported as related and those of unknown relationship. Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several MedDRA terms (MedDRA version 14.0). Except for Gr 3 and 4 infusion reactions, AE severity per NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Gr 3 - 4 infusion reactions: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=life-threatening event with same Gr 3 symptomatology, complicated by symptomatic hypotension/oxygen saturation 70% or less. Day 1=start of study drug; to 30 days after last dose of any treatment.

    Time frame: Day 1 up to 30 days after last dose

08

Results

Posted Dec 10, 2013

Participant flow

First participant, first visit: 1 July 2010; Last participant, last visit: 7 September 2012. Participants were chemotherapy-naive with Stage IV histologically or cytologically documented non-small cell lung cancer (NSCLC). Participants treated until: progressive disease (PD)/ toxicity/patient-investigator decision.

Participant flow — Overall Study
MilestoneCetuximab + Cisplatin/Vinorelbine
Started60
Completed3
Not completed57
Withdrew: Disease progression29
Withdrew: Study drug toxicity6
Withdrew: Adverse event4
Withdrew: Withdrawal by subject2
Withdrew: Maximum clinical benefit3
Withdrew: Death2
Withdrew: No longer meets criteria2
Withdrew: Participant requested to end treatment4
Withdrew: Other5

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

Time frame:
Day 1 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Deaths due to disease progression3
Deaths due to Other Causes2
SAE (any grade)38
AE (any grade)59
AE Grade 3 or 446
AE that led to Discontinuation of study drug21
PrimaryNumber of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population

Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (includes all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several preferred/other level MedDRA terms (MedDRA version 14.0). Except for Grade (GR)3 and 4 infusion reactions, AE severity were graded per the NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Severity of Gr 3 - 4 infusion reactions were: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=a life-threatening event characterized by the same symptomatology as a Gr 3, complicated by symptomatic hypotension or oxygen saturation 70% or less. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

Time frame:
Day 1 to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Grade 3-4 acneform rash5
Grade 3-4 infusion reaction2
Cardiac events Grade 3-43
Infection Grade 3-49
Sepsis Grade 3-40
Renal failure Grade 3-43
Thromboembolic events Grade 3-411
Interstitial lung disease Grade 3-40
Febrile neutropenia Grade 3-46
PrimaryNumber of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population

ULN=Upper limit of normal among all laboratory ranges. ALT=alanine transaminase; AST=aspartate aminotransferase; ALP=alkaline phosphatase. CTC grade criteria: ALT Grade 1:\>ULN 2.5\*ULN; Grade 2: \>2.5 - 5.0\*ULN; Grade 3: \>5.0 - 20.0\*ULN; Grade 4: \>20.0\*ULN. AST Grade 1: \>ULN - 2.5\*ULN; Grade 2: \>2.5 - 5.0\*ULN; Grade 3: \>5.0 - 20.0\*ULN; Grade 4: \>20.0\*ULN. Total bilirubin Grade 1: \>ULN - 1.5\*ULN; Grade 2: \>1.5 - 3.0\*ULN; Grade 3: \>3.0 - 10.0\*ULN; Grade 4: \>10.0\*ULN. Albumin (low) Grade 1:\<LLN - 3 grams per deciliter (g/dL)to \<LLN - 3 g/dL; Grade 2: \<3 - 2 g/dL to \< 3.0 - 2.0 g/dL; Grade 3: \< 2 g/dL to \<2 g/L. Day 1 (start of study drug) to 30 days after last dose of any treatment therapy, including cetuximab monotherapy.

Time frame:
Day 1 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Albumin (low) Grade 1 - 437
Albumin (low) Grade 3 or 40
Total bilirubin (high) Grade 1 - 4 (N=49)3
Total bilirubin (high) Grade 3 or 4 (N=49)0
ALT (high) Grade 1 - 431
ALT (high) Grade 3 or 40
ALP (high) Grade 1 - 426
ALP (high) Grade 3 or 40
AST (high) Grade 1 - 419
AST (high) Grade 3 or 40
PrimaryNumber of Participants With Hematology Laboratory Abnormalities - Treated Population

Hematology laboratories included hemoglobin, platelets, white blood cell (WBC) count, and absolute neutrophil count (ANC) and values were per CTC grading, 0, 1, 2, 3, 4. On-study laboratory tests were those performed after the start of study drug (from Day 2 of cycle 1) and up to 30 days after the last dose of study drug. WBC normal range: 4.1-12.3 x 10\^3 /microliter (µL); platelets normal range: 140-450 x 10\^9 /Liter (L); hemoglobin normal range 14-18 grams per deciliter (g/dL); ANC normal range: 2.03-8.36 x 10\^9/μL.

Time frame:
Day 2 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Hematology Laboratory Abnormalities - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Hemoglobin (low) Grade 1 - 451
Hemoglobin (low) Grade 3 or 44
Hemoglobin (low) Grade 40
Platelets (low) Grade 1 - 419
Platelets (low) Grade 3 or 41
Platelets (low) Grade 40
WBC (low) Grade 1 - 449
WBC (low) Grade 3 or 428
WBC (low) Grade 46
ANC (low) Grade 1 - 447
ANC (low) Grade 3 or 438
ANC (low) Grade 424
PrimaryNumber of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population

ULN=Upper limit of normal among all laboratory ranges; LLN=Lower limit of normal. CTC grade criteria: Sodium high (H) Grade (Gr) 1:\>ULN - 150 millimoles per liter (mmol/L); Gr 2: \>150 - 155 mmol/L; Gr 3: \>155 - 160mmol/L; Gr 4: \>160 mmol/L. Sodium low(L) Gr 1:\<LLN - 130mmol/L; Gr 3: \<130 - 120 mmol/L; Gr 4: \<120 mmol/L. Potassium (H) Gr 1: \>ULN - 5.5 mmol/L; Gr 2: \>5.5 - 6.0 mmol/L; Gr 3: \> 6.0 - 7.0 mmol/L; Gr 4: \>7.0 mmol/L. Potassium (L) Gr 1: \<LLN - 3.0 mmol/L; Gr 2: \<LLN - 3.0 mmol/L; Gr 3: \< 3.0 - 2.5 mmol/L; Gr 4: \<2.5 mmol/L. Serum creatinine (H) Gr 1: \>1 - 1.5\*baseline (BL)to \>ULN - 1.5\*ULN; Gr 2: \>1.5 - 3.0\*BL to \> 1.5 - 3.0\*ULN; Gr 3: \>3.0\*BL to \> 3.0 - 6.0\*ULN; Gr 4: \>6.0\*ULN. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.

Time frame:
Day 1 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Sodium (low) Grade 1 - 442
Sodium (low) Grade 3 or 418
Sodium (low) Grade 40
Sodium (high) Grade 1 - 41
Sodium (high) Grade 3 or 40
Sodium (high) Grade 40
Potassium (low) Grade 1 - 429
Potassium (low) Grade 3 or 412
Potassium (low) Grade 41
Potassium (high) Grade 1 - 410
Potassium (high) Grade 3 or 41
Potassium (high) Grade 40
Serum Creatinine (high) Grade 1 - 415
Serum Creatinine (high) Grade 3 or 40
Serum Creatinine (high) Grade 40
PrimaryNumber of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population

Drug-related AEs and drug-related SAEs (by investigator assessment) were those with a relationship to study drug(s) reported to Sponsor as related and those of unknown relationship. AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE was defined as a medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. MedDRA version 14.0. Severity of AEs were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Day 1 (start of study drug) to 30 days after last dose of any study drug, including monotherapy.

Time frame:
Day 1 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
Drug-related SAE (any grade)16
Drug-related AE (any grade)54
Drug-related AE Grade 3 or 431
Drug-related AE led to Discontinuation of drug11
PrimaryNumber of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population

Drug-related AEs (investigator assessment): those with relationship to study drug(s)reported as related and those of unknown relationship. Special interest AEs: acneform rash, infusion reaction, cardiac adverse event, febrile neutropenia, infection (all terms except sepsis), sepsis, interstitial lung disease, renal failure, and thromboembolic events. Except for interstitial lung disease, these were composite terms combining several MedDRA terms (MedDRA version 14.0). Except for Gr 3 and 4 infusion reactions, AE severity per NCI-CTC, version 3.0: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Gr 3 - 4 infusion reactions: Gr 3=symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema; Gr 4=life-threatening event with same Gr 3 symptomatology, complicated by symptomatic hypotension/oxygen saturation 70% or less. Day 1=start of study drug; to 30 days after last dose of any treatment.

Time frame:
Day 1 up to 30 days after last dose
Reported as:
Number · participants
Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population
participantsCetuximab + Cisplatin/Vinorelbine
drug-related acneform rash Grade 3 - 45
drug-related infusion reaction Grade 3 - 42
drug-related cardiac events Grade 3 - 40
drug-related infection Grade 3 - 40
drug-related sepsis Grade 3 - 40
drug-related interstitial lung disease Grade 3 - 40
drug-related renal failure Grade 3 - 42
drug-related thromboembolic events Grade 3 - 45
drug-related febrile neutropenia Grade 3 - 44

Adverse events

Collected over Day 1 up to 30 days after last dose of study drug. Participants were in the study until disease progression or toxicity/decision by patient-investigator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + Cisplatin/Vinorelbine—38/60 (63.3%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventCetuximab + Cisplatin/Vinorelbine
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/60
Febrile neutropeniaBlood and lymphatic system disorders5/60
DyspnoeaRespiratory, thoracic and mediastinal disorders4/60
Deep vein thrombosisVascular disorders3/60
Renal failureRenal and urinary disorders3/60
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/60
DehydrationMetabolism and nutrition disorders2/60
NauseaGastrointestinal disorders2/60
Pleural effusionRespiratory, thoracic and mediastinal disorders2/60
Mucosal inflammationGeneral disorders2/60
Most frequent other events
Showing 10 of 88
Most frequent other events
EventCetuximab + Cisplatin/Vinorelbine
NauseaGastrointestinal disorders41/60
FatigueGeneral disorders37/60
DyspnoeaRespiratory, thoracic and mediastinal disorders34/60
ConstipationGastrointestinal disorders31/60
HypomagnesaemiaMetabolism and nutrition disorders27/60
Dermatitis acneiformSkin and subcutaneous tissue disorders25/60
CoughRespiratory, thoracic and mediastinal disorders23/60
VomitingGastrointestinal disorders22/60
Decreased appetiteMetabolism and nutrition disorders20/60
NeutropeniaBlood and lymphatic system disorders20/60

Baseline characteristics

All treated participants.

Age, Categorical
Age, Categorical(Participants)Cetuximab + Cisplatin/Vinorelbine
<=18 years0
Between 18 and 65 years36
>=65 years24
Age, Continuous
Age, Continuous(years)Cetuximab + Cisplatin/Vinorelbine
Mean63.8 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + Cisplatin/Vinorelbine
Female23
Male37
Region of Enrollment
Region of Enrollment(participants)Cetuximab + Cisplatin/Vinorelbine
United States23
Puerto Rico7
Canada30
ECOG PS at baseline
ECOG PS at baseline(Participants)Cetuximab + Cisplatin/Vinorelbine
017
138
25
09

Study locations

22 sites
  • Donald W. Hill M.D., P.C.
    Casa Grande, Arizona 85122, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • Cancer Care Institute
    Los Angeles, California 90036, United States
  • Northern California Hematology & Oncology
    Oakland, California 94609, United States
  • Sharp Clinical Oncology Research
    San Diego, California 92123, United States
  • Broward Oncology Associates, P.A.
    Ft. Lauderdale, Florida 33308, United States
  • Elite Research Institute
    Miami, Florida 33125, United States
  • Edward H. Kaplan, MD & Associates
    Skokie, Illinois 60076, United States
  • Fairview Southdale Medical Oncology Clinic
    Edina, Minnesota 55435, United States
  • Mid Dakota Clinic, Pc
    Bismarck, North Dakota 58501, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • University Medical Center
    Lubbock, Texas 79415, United States
  • Columbia Basin Hematology and Oncology
    Kennewick, Washington 99336, United States
  • The Moncton Hospital
    Moncton, New Brunswick E1C 6Z8, Canada
  • Local Institution
    Grand Falls-Windsor, Newfoundland and Labrador A2A 2E2, Canada
  • The Credit Valley Hospital
    Mississauga, Ontario L5M 2N1, Canada
  • Sudbury Regional Hospital
    Sudbury, Ontario P3E 5J1, Canada
  • Thunder Bay Regional Health Sciences Centre (Regional Cancer Care)
    Thunder Bay, Ontario P7B 6V4, Canada
  • Toronto East General Hospital
    Toronto, Ontario M4C 3E7, Canada
  • Centre de sante et de services sociaux de Rimouski-Neigette
    Rimouski, Quebec G5L 5T1, Canada
  • Ponce School of Medicine (Caimed Center)
    Ponce, 00716, Puerto Rico
  • Fundacion de Investigacion de Diego
    San Juan, 00927, Puerto Rico
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 23, 2010
Start
Jul 2010
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Dec 10, 2013
Last update
Dec 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01109524
Responsible party
Sponsor
First posted
Apr 23, 2010
Start date
Jul 2010
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Dec 10, 2013
Last update
Dec 24, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin · Vinorelbine

Start the discussion